TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers-Reference-Cited by-同舟云学术

TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers

Published:2024-03-27 Issue:8007 Volume:628 Page:416-423
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Nichakawade Tushar D.^ORCID,Ge Jiaxin^ORCID,Mog Brian J.^ORCID,Lee Bum Seok,Pearlman Alexander H.^ORCID,Hwang Michael S.,DiNapoli Sarah R.,Wyhs Nicolas,Marcou Nikita^ORCID,Glavaris Stephanie,Konig Maximilian F.^ORCID,Gabelli Sandra B.^ORCID,Watson Evangeline,Sterling Cole,Wagner-Johnston Nina,Rozati Sima,Swinnen Lode,Fuchs Ephraim,Pardoll Drew M.^ORCID,Gabrielson Kathy,Papadopoulos Nickolas^ORCID,Bettegowda Chetan^ORCID,Kinzler Kenneth W.,Zhou Shibin^ORCID,Sur Surojit,Vogelstein Bert^ORCID,Paul Suman^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41586-024-07233-2.pdf

Reference54 articles.

1. June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).

2. Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651–668 (2020).

3. Zahavi, D. & Weiner, L. Monoclonal antibodies in cancer therapy. Antibodies https://doi.org/10.3390/antib9030034 (2020).

4. Fu, Z., Li, S., Han, S., Shi, C. & Zhang, Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct. Target. Ther. 7, 93 (2022).

5. Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934–941 (2022).

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “Clone-specific” antibody-drug conjugates: an innovative strategy in the treatment of T-cell cancers;Signal Transduction and Targeted Therapy;2024-09-04

2. Appropriate interpretation of TRBC1‐dim positive subsets in T‐cell immunophenotyping by flow cytometry;Cytometry Part B: Clinical Cytometry;2024-09-02

3. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting;Molecular Therapy;2024-09

4. Pre-TCR-Targeted Immunotherapy for T-cell Acute Lymphoblastic Leukemia;2024-06-02

5. Selective targeting of malignant T cells;Nature Cancer;2024-05-30